https://vitasmlab.net

COVMARK2

Coronaviruses Targeted Library (July 2026 update)

Coronaviruses are a major global health threat, causing diseases ranging from the common cold to severe outbreaks like SARS, MERS, and COVID-19. Their high mutation rate and zoonotic potential enable frequent emergence of novel variants, evading immunity and challenging existing therapies. While vaccines have been pivotal, their efficacy can wane against evolving strains, and antiviral treatments like Paxlovid face limitations due to resistance risks and narrow activity spectra. Broad-spectrum antivirals targeting conserved viral proteins or host pathways could address these gaps, ensuring prepared- ness for future outbreaks. Drug discovery efforts must prioritize pan-coronavirus inhibitors and host-directed therapies to combat current and future variants, reducing pandemic risks and alleviating chronic health burdens. Investing in next-gener- ation antivirals is critical to safeguarding public health against this ever-evolving viral family.



Example Targets:

SARS-CoV-2 (COVID-19)

SARS-CoV-1

MERS-CoV Common Cold Coronaviruses



STK671354



STL113103



STL366151

Coronaviruses Targeted Library (COVMARK2) consists of compounds with potential antiviral activity, which were selected based on similarity to known effectors of coronaviral proteins. This library was designed to provide a potential starting point or to expand ongoing drug discovery project. It is designed in a way that maximizes structural diversity and excludes problematic compounds. This library has 16340 compounds. All compounds follow RO5.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at

irina@vitasmlab.biz

Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!

Empowering Your Research, One Molecule at a Time.